SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 27, 1997
KOS PHARMACEUTICALS, INC.
-------------------------
(Exact name of registrant as specified in its charter)
FLORIDA 000-22171 65-0670898
------- --------- ----------
(State or other (Commission (IRS Employer
jurisdiction of File No.) Identification
incorporation) No.)
1001 BRICKELL BAY DRIVE
25TH FLOOR
MIAMI, FLORIDA 33131
(Address of principal executive offices)
305-577-3464
------------
(Registrant's telephone number, including area code)
<PAGE>
ITEM 8. CHANGE IN FISCAL YEAR.
On August 27, 1997, the Board of Directors of the registrant voted to
change the registrant's fiscal year end from June 30 to December 31, beginning
with a short fiscal year ending on December 31, 1997. A transition report for
the period from July 1, 1997, through December 31, 1997, will be filed on
Form 10-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
KOS PHARMACEUTICALS, INC.
By: /s/ DANIEL M. BELL
---------------------------------
Daniel M. Bell
President and Chief Executive Officer
Dated: September 2, 1997
